Houston-based medtech company BiVACOR has picked up $22 million in funding — in the form of a series B round and a federal grant — to propel development of its Total Artificial Heart device for treatment of severe heart failure.

In a May 19 news release, BiVACOR says it received a series B round of $19 million and a National Institutes of Health grant of $3 million. Boston-based Cormorant Asset Management and Australia's OneVentures, through its OneVentures Healthcare Fund III, led the round.

OneVentures first invested in BiVACOR three years ago. According to Australia's Financial Review, OneVentures initially pumped $3 million (Australian dollars) into BiVACOR, with the potential of contributing as much as $10 million if BiVACOR met certain milestones. BiVACOR received a round of seed funding from U.S. investors in 2013.

"BiVACOR's one-of-a-kind technology is supported by a remarkable team that has moved this technology a significant distance toward the clinic," Paul Kelly, managing partner of OneVentures, says in BiVACOR's news release.

The fresh cash will support preparation for the first human trials of the device. As a short-term measure, the device can be implanted in someone awaiting a heart transplant. It's also designed to be a long-term alternative to a heart transplant.

The BiVACOR device, billed as the first long-term therapy for patients with severe heart failure, is an implantable artificial heart based on rotary blood-pump technology. Similar in size to an adult fist, it is small enough to be implanted in many women and some children yet capable of delivering enough cardiac power to a man who's exercising. Unlike the two-chamber human heart, BiVACOR's device features a single chamber.

"The commitment and interest from our investors validate our technology and the need for improved options to treat end-stage biventricular heart failure," says Daniel Timms, founder and CEO of BiVACOR. "With this financing, we will be able to expand our world-class team and undertake … verification activities so that we can commence our first-in-human early feasibility study in the near future."

Founded in 2008, BiVACOR maintains offices in Cerritos, California, and Brisbane, Australia. The company is affiliated with Houston's Texas Heart Institute, where the world's first artificial heart was implanted. BiVACOR's headquarters is at the Texas Medical Center complex.

The company employs about a dozen people and says the funding will enable it to bring on another 10 employees.

For 13 years, BiVACOR has been working on technology aimed at eliminating the need for heart transplants. Thus far, the BiVACOR device has been tested only on cows.

"In heart failure, the heart becomes unable to pump enough blood to keep the body healthy and strong. At least 26 million people around the world are living with the disease, and the number is rising as populations age," IEEE Spectrumreported in 2019. "Patients with severe heart failure have a bleak outlook: Their best option is a heart transplant, but the limited number of donor hearts means that only about 5,000 patients around the world receive transplants each year. Thousands more patients are eligible for transplants, and some die while waiting for a donor organ."